Toll Free: 1-888-928-9744

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 504 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016', provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
- The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects
- The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Amyotrophic Lateral Sclerosis Overview 8 Therapeutics Development 9 Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 11 Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 20 Amyotrophic Lateral Sclerosis - Pipeline Products Glance 22 Amyotrophic Lateral Sclerosis - Products under Development by Companies 26 Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 34 Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 37 Amyotrophic Lateral Sclerosis - Therapeutics Assessment 122 Drug Profiles 139 Amyotrophic Lateral Sclerosis - Recent Pipeline Updates 380 Amyotrophic Lateral Sclerosis - Dormant Projects 462 Amyotrophic Lateral Sclerosis - Dormant Projects 462 Amyotrophic Lateral Sclerosis - Discontinued Products 472 Amyotrophic Lateral Sclerosis - Product Development Milestones 474 Appendix 484
List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2016 28 Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 31 Number of Products under Development by Companies, H1 2016 (Contd..1) 32 Number of Products under Development by Companies, H1 2016 (Contd..2) 33 Number of Products under Development by Companies, H1 2016 (Contd..3) 34 Number of Products under Development by Companies, H1 2016 (Contd..4) 35 Number of Products under Development by Companies, H1 2016 (Contd..5) 36 Number of Products under Development by Companies, H1 2016 (Contd..6) 37 Number of Products under Development by Companies, H1 2016 (Contd..7) 38 Number of Products under Investigation by Universities/Institutes, H1 2016 40 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Development, H1 2016 43 Comparative Analysis by Unknown Stage Development, H1 2016 44 Products under Development by Companies, H1 2016 45 Products under Development by Companies, H1 2016 (Contd..1) 46 Products under Development by Companies, H1 2016 (Contd..2) 47 Products under Development by Companies, H1 2016 (Contd..3) 48 Products under Development by Companies, H1 2016 (Contd..4) 49 Products under Development by Companies, H1 2016 (Contd..5) 50 Products under Development by Companies, H1 2016 (Contd..6) 51 Products under Development by Companies, H1 2016 (Contd..7) 52 Products under Investigation by Universities/Institutes, H1 2016 53 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 54 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 55 Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2016 56 Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H1 2016 57 Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H1 2016 58 Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp., H1 2016 59 Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp., H1 2016 60 Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H1 2016 61 Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H1 2016 62 Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc., H1 2016 63 Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc., H1 2016 64 Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2016 65 Amyotrophic Lateral Sclerosis - Pipeline by Biogen, Inc., H1 2016 66 Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016 67 Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 68 Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H1 2016 69 Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 70 Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H1 2016 71 Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H1 2016 72 Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Inc., H1 2016 73 Amyotrophic Lateral Sclerosis - Pipeline by Daval International Limited, H1 2016 74 Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals, Inc., H1 2016 75 Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H1 2016 76 Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2016 77 Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 78 Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma, Inc., H1 2016 79 Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc., H1 2016 80 Amyotrophic Lateral Sclerosis - Pipeline by Gemac, H1 2016 81 Amyotrophic Lateral Sclerosis - Pipeline by Genentech, Inc., H1 2016 82 Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 83 Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H1 2016 84 Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex S.A., H1 2016 85 Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H1 2016 86 Amyotrophic Lateral Sclerosis - Pipeline by Grifols, S.A., H1 2016 87 Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H1 2016 88 Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H1 2016 89 Amyotrophic Lateral Sclerosis - Pipeline by IntelliCell BioSciences Inc., H1 2016 90 Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 91 Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 92 Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd., H1 2016 93 Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 94 Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H1 2016 95 Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H1 2016 96 Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 97 Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 98 Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H1 2016 99 Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corporation, H1 2016 100 Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2016 101 Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H1 2016 102 Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H1 2016 103 Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H1 2016 104 Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H1 2016 105 Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 106 Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H1 2016 107 Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016 108 Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2016 109 Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H1 2016 110 Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H1 2016 111 Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H1 2016 112 Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H1 2016 113 Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H1 2016 114 Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica Plc, H1 2016 115 Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H1 2016 116 Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H1 2016 117 Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc., H1 2016 118 Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2016 119 Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm, Inc., H1 2016 120 Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H1 2016 121 Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H1 2016 122 Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H1 2016 123 Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 124 Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016 125 Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 126 Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 127 Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed S.L., H1 2016 128 Amyotrophic Lateral Sclerosis - Pipeline by Symic Biomedical, Inc., H1 2016 129 Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 130 Amyotrophic Lateral Sclerosis - Pipeline by Thera Neuropharma, Inc., H1 2016 131 Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H1 2016 132 Amyotrophic Lateral Sclerosis - Pipeline by UCB S.A., H1 2016 133 Amyotrophic Lateral Sclerosis - Pipeline by UniQure N.V., H1 2016 134 Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 135 Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H1 2016 136 Amyotrophic Lateral Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 137 Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics, Inc., H1 2016 138 Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd., H1 2016 139 Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 140 Assessment by Monotherapy Products, H1 2016 141 Assessment by Combination Products, H1 2016 142 Number of Products by Stage and Target, H1 2016 144 Number of Products by Stage and Mechanism of Action, H1 2016 150 Number of Products by Stage and Route of Administration, H1 2016 155 Number of Products by Stage and Molecule Type, H1 2016 157 Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H1 2016 399 Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2016 481 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H1 2016 482 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H1 2016 483 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H1 2016 484 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H1 2016 485 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H1 2016 486 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H1 2016 487 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H1 2016 488 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H1 2016 489 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..9), H1 2016 490 Amyotrophic Lateral Sclerosis - Discontinued Products, H1 2016 491 Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H1 2016 492


List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2016 28 Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 30 Number of Products under Investigation by Universities/Institutes, H1 2016 39 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Products, H1 2016 43 Assessment by Monotherapy Products, H1 2016 141 Assessment by Combination Products, H1 2016 142 Number of Products by Top 10 Targets, H1 2016 143 Number of Products by Stage and Top 10 Targets, H1 2016 143 Number of Products by Top 10 Mechanism of Actions, H1 2016 149 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 149 Number of Products by Top 10 Routes of Administration, H1 2016 154 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 154 Number of Products by Top 10 Molecule Types, H1 2016 156 Number of Products by Stage and Top 10 Molecule Types, H1 2016 156

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify